SCHEMBL17153233

SCHEMBL17153233

COCCN(CCNc1ccc(-c2ccnc(Nc3cccc(CN4CCN(CC(=O)OC(C)(C)C)CC4)c3)n2)cn1)C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 7/20 0.44
JAK3 P52333 6/20 0.44
ABL1 P00519 4/20 0.42
BCR P11274 4/20 0.42
PDGFRB P09619 1/20 0.42
SRC P12931 1/20 0.42
PDGFRA P16234 1/20 0.42
SYK P43405 1/20 0.42
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
PRKD3 O94806 1/20 0.39
EGFR P00533 1/20 0.39
PRKCG P05129 1/20 0.39
PRKCB P05771 1/20 0.39
LCK P06239 1/20 0.39
PRKCA P17252 1/20 0.39
PRKCH P24723 1/20 0.39
PRKCI P41743 1/20 0.39
ZAP70 P43403 1/20 0.39
PRKCE Q02156 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17152976 0.87 PRKCA (0.44) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL17153141 0.86 JAK2 (0.44) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL17153228 0.85 JAK2 (0.48) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL17153076 0.84 JAK2 (0.47) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL17152992 0.83 JAK2 (0.45) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL17152973 0.83 PRKCA (0.43) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL17153012 0.83 JAK2 (0.48) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL17153272 0.82 TBK1 (0.44) JAK2JAK3TBK1
SCHEMBL17152812 0.81 JAK2 (0.47) JAK2JAK3ABL1BCRPDGFRB
SCHEMBL17153010 0.81 JAK2 (0.53) JAK2JAK3ABL1BCRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017509-B2 Macrocylic pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2018-07-10 US disclosed
US-10017509-B2 Macrocylic pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2018-07-10 US disclosed
EP-3126364-B1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2018-02-07 EP disclosed
US-20170022202-A1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-01-26 US disclosed
WO-2015150555-A1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022202-A1 MACROCYLIC PYRIMIDINE DERIVATIVES EEF2K, VPS26B, VPS28 JAK2 2654/4885JAK3 3104/4885ABL1 3037/4885
US-10017509-B2 Macrocylic pyrimidine derivatives EEF2K, VPS26B, VPS28 JAK2 2654/4885JAK3 3104/4885ABL1 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.